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Background: 3⬘ repair exonuclease 1 (TREX1) is a DNase involved in autoimmune disorders and the antiviral response.
Results: TREX1 also degrades single-stranded RNA or RNA in a RNA/DNA hybrid molecule.
Conclusion: TREX1 is a human homolog of Escherichia coli RNase T.
Significance: The novel RNase activity of TREX1 is crucial for understanding its physiological role.

3⬘ repair exonuclease 1 (TREX1)3 is the most abundant 3⬘ to
5⬘ DNA exonuclease in mammalian cells (1–3). Mutations in
TREX1 cause autoimmune disorders, including Aicardi-Goutieres syndrome (AGS) type 1, systemic lupus erythematosus,
chilblain lupus, and retinal vasculopathy with cerebral leukodystrophy (4 – 8). Failure to degrade cytosolic DNA was
believed to be the principal cause of TREX1-mediated autoimmune diseases (9 –11). Additionally, recent data showed that
defects in TREX1 also conferred resistance to RNA viruses
including human immunodeficiency virus (HIV), vesicular stomatitis virus, influenza virus, West Nile virus, and Sendai virus
(12, 13).
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3
The abbreviations used are: TREX1, 3⬘ repair exonuclease 1; AGS, AicardiGoutieres syndrome; ssRNA, single-stranded RNA; ssDNA, single-stranded
DNA; dsRNA, double-stranded RNA; nt, nucleotide.
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Intriguingly, TREX1 resembles bacterial RNase T, a founding
member of the DEDD superfamily of exoribonucleases, not
only in its primary sequence (1, 14), but also in that both TREX1
and RNase T are active as homodimers (1, 15, 16). Inasmuch as
RNase T plays an important role in Escherichia coli RNA
metabolism including tRNA end turnover and 3⬘ maturation of
tRNAs and rRNAs, and also exhibits high affinity and robust
exonuclease activity on DNA like all other members of the
DEDD superfamily (14, 17), we speculated that TREX1 also
might have exoribonuclease activity. This was of particular
interest because of the involvement of TREX1 in the autoimmune response to cellular nucleic acids as well as its immune
response to RNA viruses (9, 10, 12, 13). However, in earlier
work exoribonuclease activity was not detected for TREX1 (1).
Nevertheless, we thought it would be worthwhile to reevaluate the biochemical activity of TREX1. To do this, we designed
a novel protocol to overexpress and purify full-length human
TREX1 from insect cells. In the previous work, TREX1 was
expressed in the bacterium, E. coli, and was not the full-length
protein (1, 18). Using the insect-cell purified protein, we demonstrate here that TREX1 has 3⬘ to 5⬘ exoribonuclease activity
on single-stranded RNA (ssRNA) and on DNA/RNA hybrids,
but not on double-stranded RNA (dsRNA). Interestingly,
human TREX1 and E. coli RNase T share strikingly similar catalytic properties, and based on our observations, we believe
they are homologs. Possible roles for the exoribonuclease activity of TREX1 in cellular RNA metabolism and in immunity to
RNA viruses are discussed.

Experimental Procedures
Protein Expression, Fractionation, and Purification—The
identity of human TREX1 cDNA was confirmed by sequencing
and found to match exactly the open reading frame of NCBI
Reference Sequence NM_033629 (isoform b) (2). The TREX1D200N mutant was created by using the QuikChange site-directed mutagenesis kit (Agilent Technologies). Overexpression
of non-tagged TREX1 was carried out in insect High Five cells
using the Bac-to-Bac expression system (Invitrogen). Expression of TREX1 was confirmed by Western blot analysis usVOLUME 290 • NUMBER 21 • MAY 22, 2015
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3ⴕ repair exonuclease 1 (TREX1) is a known DNA exonuclease
involved in autoimmune disorders and the antiviral response. In
this work, we show that TREX1 is also a RNA exonuclease. Purified TREX1 displays robust exoribonuclease activity that
degrades single-stranded, but not double-stranded, RNA.
TREX1-D200N, an Aicardi-Goutieres syndrome disease-causing mutant, is defective in degrading RNA. TREX1 activity is
strongly inhibited by a stretch of pyrimidine residues as is a
bacterial homolog, RNase T. Kinetic measurements indicate
that the apparent Km of TREX1 for RNA is higher than that for
DNA. Like RNase T, human TREX1 is active in degrading native
tRNA substrates. Previously reported TREX1 crystal structures
have revealed that the substrate binding sites are open enough to
accommodate the extra hydroxyl group in RNA, further supporting our conclusion that TREX1 acts on RNA. These findings
indicate that its RNase activity needs to be taken into account
when evaluating the physiological role of TREX1.

WT
170
130
95
72
55
43

170
130
95
72
55
43

175
83
62

D200N

WT

D200N

Marker

-40
tos
N u olic
cle
Sa a r
lt +
NP

B

Cy

Cy

A

tos
N u olic
cle
Sa a r
lt +
Ma NP
rke -40
r

TREX1 Is Also an Exoribonuclease

34

34

26

26

17

17

10

10

48

33
25

Western

SDS-PAGE

C

TREX1-WT
4 8 16 32

0

TREX1-D200N
4 8 16 32

D
20

Protein 0
(nM)

TREX1-WT
4 8 16 32

0

TREX1-D200N
4 8 16 32
4
3

10
2

% Sub 100 96 82 62 10

% Sub 100 89 45

11

2

100 100 100 100 100

100 100 100 100 100

FIGURE 1. Purified human TREX1 displays exoribonuclease activity on ssRNA. A, SDS-PAGE and Western blots of fractionated TREX1-containing extracts
(40 g each lane). Salt ⫹ Nonidet P-40 indicates the TREX1 protein samples after osmotic and detergent treatments. Arrows point to TREX1. Protein markers in
kilodaltons are indicated. B, SDS-PAGE and Western analysis of the purified WT and D200N TREX1 proteins. The PAGE gel was stained with Coomassie Brilliant
Blue R-250. Arrows point to the purified TREX1. Protein markers in kilodaltons are indicated. C, titration of TREX1-WT and TREX1-D200N proteins on a
20-nucleotide ssRNA substrate (2 nM) labeled at its 5⬘ end by [␥-32P]ATP using T4 polynucleotide kinase. Reaction time is 10 min. Arrows point to positions of
the substrate and a 10-nt standard. % Sub indicates the percentage of the remaining substrate. D, activity of TREX1-WT and D200N on a 4-nucleotide poly(A)
RNA substrate (2 nM) labeled at its 5⬘ end. Reaction time is 10 min. Arrows point to position of the 4-nt substrate and positions of the 2- and 3-nt standards.

ing a Pierce ECL kit (Pierce). Antibody against TREX1 was
purchased from Santa Cruz Biotechnology (Dallas, TX)
(SC-271870).
Upon expression of human TREX1, the insect cells were
resuspended in a hypotonic buffer (20 mM Hepes-KOH, pH 7.5,
0.5 mM MgCl2, 5 mM KCl, 5 mM ␤-mercaptoethanol, and a
mixture of protease inhibitors (19)). Nuclei were separated
from the cytoplasm of insect cells by homogenization on ice
using 10 strokes of a Dounce homogenizer followed by centrifugation at 4,200 rpm (Beckman Coulter rotor JLA-10.500) at
4 °C for 6 min. The nuclear pellet was re-suspended in a cold
hypertonic buffer (20 mM Hepes-KOH, pH 7.5, 10% sucrose,
500 mM NaCl, 5 mM ␤-mercaptoethanol, and the mixture of
protease inhibitors), incubated on ice for 10 min, and centrifuged at 12,000 rpm (Beckman Coulter rotor JA-25.50) at 4 °C
for 30 min. The precleaned nuclei were then resuspended in the
hypertonic buffer containing 0.5% Nonidet P-40, incubated on
ice for 10 min, and centrifuged at 16,000 rpm (Beckman Coulter
rotor JA-25.50) at 4 °C for 1 h.
MAY 22, 2015 • VOLUME 290 • NUMBER 21

The supernatant fraction containing TREX1 was desalted to
100 mM KCl in buffer Q (50 mM KPO4, pH 7.4, 0.5 mM EDTA,
0.01% Nonidet P-40, 10% glycerol, 2 mM DTT and protease
inhibitors) and loaded onto a 5-ml Q-Sepharose column. The
flow-through from the Q-Sepharose column was directly
loaded onto a 1-ml Mono S column (GE Healthcare) in buffer
Q. The Mono S column was then resolved using a 30-ml 100 to
500 mM KCl gradient. TREX1 was eluted at ⬃280 mM KCl. The
pooled TREX1 was concentrated by ultracentrifugation and
loaded on a Superdex 200 column (GE Healthcare) in buffer Q
with 160 mM KCl. Depending on the purity of TREX1 after
Superdex chromatography, it can be further purified on a
ssDNA cellulose column using 330 mM KCl for elution from the
column. TREX1 protein was followed by SDS-PAGE and Western blot analysis throughout the purification process. Mutant
TREX1-D200N was purified using the same protocol as for the
wild-type protein. Protein concentration was determined by
the Coomassie (Bradford) Protein Assay Reagent (Pierce). The
purified protein was stored in aliquots at ⫺80 °C.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. Effect of metal ions on the exonuclease activity of TREX1. The experiments were done using 16 nM purified human TREX1 for RNA and 1 nM for
DNA, and the indicated oligo substrates (2 nM). The cations were added to the reaction mixture at a final concentration of 3 mM. Incubation time is shown on
the top. % Sub indicates the percentage of the remaining substrate. P indicates the 32P labeling.

Oligonucleotide Substrates and Exonuclease Assays—RNA
and DNA oligos were synthesized by Integrated DNA Technology and Sigma, respectively. The sequence of the 20-nucleotide single-stranded RNA (ssRNA) is 5⬘-GACGCUGCCGAAUUCUACCA-3⬘. The sequence of the 20-nucleotide
ssDNA is 5⬘-GACGCTGCCGAATTCTACCA-3⬘. We also
used poly(A)17, poly(U)17, poly(C)17, and poly(A)4 RNA oligos
(20) and poly(dA)17, poly(dT)17, and poly(dC)17 DNA oligos.
All oligos were 32P-labeled at their 5⬘ end using phage T4 poly-

13346 JOURNAL OF BIOLOGICAL CHEMISTRY

nucleotide kinase (New England Biolabs) and [␥-32P]ATP. For
nuclease assays, a specified amount of RNA or DNA substrate was
incubated with an indicated amount of protein in a 5-l reaction
mixture containing 25 mM Hepes-KOH, pH 7.6, 1 mM DTT, 3 mM
MgCl2, 6.5% glycerol, 120 g/ml of BSA, and 100 mM KCl. After
incubation for the specified time at 37 °C, the reaction was terminated by adding 5 l of sequencing dye with 0.2% SDS and denaturing at 90 °C for 3 min, followed by resolution using a 20% denaturing sequencing gel and analyzed by autoradiography.
VOLUME 290 • NUMBER 21 • MAY 22, 2015
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FIGURE 2. TREX1 action on RNA and RNA/DNA hybrid substrates. The experiments were done using 16 nM purified human TREX1 for RNA, the indicated
oligo substrates (2 nM), and an increasing incubation time. Arrows point to substrate position and 1-nt standard. % Sub indicates the percentage of remaining
substrate. P in a circle and stars indicate the 32P labeling. Green, RNA; black, DNA.
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FIGURE 4. TREX1 discriminates against pyrimidines in RNA. Time course experiment using 16 nM purified human TREX1 and TREX1-D200N (for A17 only) and
the indicated DNA (A) and RNA (B) substrates (2 nM, green, RNA; black, DNA).

Determination of Kinetic Parameters—To measure kinetic
parameters, the analyses were repeated three times using
increasing amounts of the 20-nt ssRNA (1 nM, 10 nM, 100 nM, 1
M, and 10 M) or ssDNA substrate (1, 3, 9, 27, 81, and 243 nM).
In the presence of TREX1 (16 nM for ssRNA and 0.4 nM for
ssDNA), the reaction was carried out for 20 min at 37 °C. Data
were fitted to the Michaelis-Menten equation: v ⫽ Vmax[S]/
(Km ⫹ [S]), where v is the reaction rate and [S] is the concentration of substrate. Km and Vmax were determined by plotting v
against [S] using Origin software through nonlinear curve fitting. kcat was calculated by Vmax/[E], where [E] is the enzyme
concentration. Quantitation of the nucleic acid excision was
carried out using Image J.
Nuclease Assay on tRNA—The reactions were carried out
with the addition of 4 nM TREX1 protein and 9.3 M of a mixture of tRNA-CC[3H]As (21). The 30-l reaction mixtures were
incubated at 37 °C for 30 min. The reaction was stopped by the
addition of 150 l of 0.5% (w/v) yeast RNA and 200 l of 10%
trichloroacetic acid. The sample was placed in ice for 30 min
MAY 22, 2015 • VOLUME 290 • NUMBER 21

and then centrifuged at 16,000 ⫻ g for 15 min at 4 °C. The
radioactivity in 200 l of the supernatant fraction was determined by liquid scintillation counting using a LS 6500 multipurpose scintillation counter (Beckman Coulter, Inc.).

Results
Purification of Non-tagged Human TREX1 Protein—To
examine the nuclease activity of native human TREX1, we
developed a simple protocol for enriching and purifying the
non-tagged, full-length protein from insect cells in which it was
overexpressed (Fig. 1A). Isolated nuclei, which contain a large
amount of TREX1 (Fig. 1A), were treated with a high salt concentration (500 mM NaCl), which results in nuclear shrinkage
and forces most nuclear matrix proteins out of the nuclei. The
“shrunken” nuclei were then treated with 0.5% Nonidet P-40
and 500 mM salt for release of nuclear membrane-associated
and chromatin-associated proteins. This procedure greatly
enriches the TREX1 protein sample before column purification
(Fig. 1A, compare salt ⫹ Nonidet P-40 lanes with nuclear lanes).
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 5. Kinetic analysis of TREX1 on ssRNA and ssDNA and comparison of its DNA and RNA exonuclease activity. A, TREX1 activity on 20-nucleotide
ssDNA (black) or ssRNA (green) substrate (2.4 M). The reaction time is 10 min. Arrows point to substrate position and position of GMP. % Sub indicates the
percentage of remaining substrate. P in a circle indicates the 32P labeling. B, kinetic measurement of TREX1. In the presence of 16 nM TREX1, ssDNA, or ssRNA
were added at varying concentrations (“Experimental Procedures”) in a 20-min reaction. Data were fitted to the Michaelis-Menten equation and Km and kcat
were calculated as described under “Experimental Procedures.“ C, activity of TREX1 on tRNA. 4 nM TREX1 protein was incubated with 9.3 M tRNA-CC[3H]A at
37 °C for 30 min. The radioactivity in 200 l of the supernatant fraction was determined by liquid scintillation counting. Error bars, standard deviation.

The non-tagged TREX1-WT and TREX1-D200N mutant proteins were then purified to homogeneity using Q-Sepharose,
Mono S, Superdex 200, and ssDNA columns. Western analysis
confirmed that both homogeneous proteins were indeed
TREX1 (Fig. 1B).
Human TREX1 Has Exoribonuclease Activity—After verifying the DNA exonuclease activity of the purified protein (see
examples in Figs. 3, 4A, and 5A), we investigated whether
TREX1 also has ribonuclease activity by incubating the protein

13348 JOURNAL OF BIOLOGICAL CHEMISTRY

with a 5⬘-end labeled 20-nt long RNA (see “Experimental Procedures” for sequence). As shown in Fig. 1C, TREX1 showed
distributive exoribonuclease activity on this RNA substrate that
increased with increasing concentrations of enzyme. At the
highest levels of TREX1 protein (16 and 32 nM), almost all of the
RNA oligo was converted to shorter fragments due to removal
of residues from its 3⬘ end. In contrast, the D200N mutant of
TREX1, which lacks DNA exonuclease activity and leads to
AGS disease (9, 10, 22), is completely defective in shortening
VOLUME 290 • NUMBER 21 • MAY 22, 2015
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FIGURE 6. Mouse TREX1 structure shows that this enzyme can bind RNA
substrates. A, ribbon structure of the mouse TREX1 (TREX1-D200N; Protein
Data Bank code 3U6F (9)) shows a dimeric protein that binds nucleic acid
substrates on two oppositely positioned solvent-exposed clefts (DNA substrate from this structure is shown in a stick representation). The binding sites
are open enough to accommodate the 2⬘ OH in an RNA substrate (approximate expected positions of the 2⬘ oxygen atoms are marked by stars; Mg at
the active site is shown as a sphere, and an active site Asp is shown as sticks).
The closest approach between the enzyme and the 2⬘ positions on the
nucleic acid substrate is at the 3⬘ end. This position (residue 81 in human
TREX1) is always a short side chain (alanine), which provides enough space to
accommodate a 2⬘ hydroxyl. B, a molecular surface view showing one of the
substrate binding clefts of TREX1. The molecular surface is colored by electrostatic charge using PyMol (31).

ner. However, TREX1 appears to show stronger activity on
ssDNA, being ⬃10-fold more active on DNA under the specific
experimental conditions (compare 10 and 100 nM lanes on
DNA and RNA (2.4 M), respectively, in Fig. 5A).
To determine the catalytic property, we measured the kinetic
constants of TREX1 on ssRNA and ssDNA. The apparent Km of
TREX1 for ssRNA is 5.28 M (Fig. 5B), comparable with that of
E. coli RNase T (10 M) (24). This is considerably higher than
the Km of TREX1 for ssDNA (0.22 M, Fig. 5B, and 19 nM in Ref.
18), and again resembles E. coli RNase T in terms of affinity for
RNA and DNA substrates (17). Interestingly, the kcat of TREX1
for ssRNA is very similar to that for ssDNA (Fig. 5B). Thus, the
resulting overall enzyme efficiency of TREX1 for ssDNA is
⬃30-fold higher than for ssRNA (Fig. 5B, kcat/Km). These
kinetic parameters indicate that the DNase activity of TREX1 is
not dramatically stronger than its RNase activity (similar kcat),
but it is more efficient on ssDNA due to its higher substrate
affinity to DNA (lower Km).
TREX1 Acts on tRNA—RNase T plays an important role in
E. coli tRNA end turnover and 3⬘ maturation of tRNAs and
JOURNAL OF BIOLOGICAL CHEMISTRY
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the ssRNA substrate (Fig. 1C). Inasmuch as the WT and mutant
proteins were purified using the same procedure, these data
also indicate that the RNase activity is a property of TREX1 and
not a contaminating protein. Additionally, an N-terminal hexahistidine-tagged version of TREX1 that was purified through a
different protocol (nickel and Mono S columns) shows similar
RNase activity (data not shown).
Under the incubation conditions used in Fig. 1C, most of the
degradation products derived from the 20-nt ssRNA substrate
were longer than 10 nucleotides. To examine whether TREX1
also can degrade a small RNA substrate, we incubated TREX1
with a 4-nucleotide oligo, A4 (Fig. 1D). Although TREX1 is
about 2–3-fold less active on the 4-nucleotide substrate than
the 20-nucleotide RNA (compare Fig. 1, C with D), it effectively
shortens A4 to A3 and A2, indicating that TREX1 can digest
even very small RNAs. Again, the D200N mutant is completely
defective in shortening the A4 substrate (Fig. 1D), confirming
that the activity on A4 is due to TREX1.
TREX1 Cleaves the RNA in a RNA/DNA hybrid, but Is Inactive on Double-stranded RNA—In early work, TREX1 was
shown to have strong exonuclease activity on dsDNA (18). To
determine whether TREX1 also can degrade dsRNA, we examined its activity on a variety of substrates using 16 nM TREX1.
Although TREX1 rapidly degrades ssRNA in a time-dependent
manner, it is inactive on the dsRNA counterpart with no loss of
substrate even after 20 min of incubation (Fig. 2). This observation is similar to what was reported for E. coli RNase T (23),
another exoribonuclease of the DEDD family. In contrast,
TREX1 is able to degrade the RNA strand in an RNA/DNA
hybrid molecule, although the activity is lower than that on
ssRNA. It is likely that RNA degradation in the DNA-RNA
hybrid is due to release of ssRNA following rapid degradation of
the DNA strand, because, as shown in Fig. 2, the DNA strand is
completely degraded in 2 min, whereas degradation of the RNA
strand is just beginning at that time.
As previously observed for its DNA exonuclease activity (Fig.
3, bottom panel, and Ref. 18), TREX1 requires Mg2⫹ for optimal
RNase activity (Fig. 3, top panel). Other cations, Mn2⫹, Co2⫹,
Zn2⫹, Cu2⫹, and Ca2⫹ are unable to stimulate activity when
present at 3 mM.
The Exoribonuclease Activity of TREX1 Displays a Dramatic
Base Specificity—E. coli RNase T is known to display strong
base specificity and to discriminate against pyrimidine nucleotides (23). Consequently, we investigated the action of TREX1
on ssRNA oligos with different base compositions. In contrast
to its DNA exonuclease activity, which acts almost equally on
dC17, dT17, and dA17 (Fig. 4A), the RNase activity of TREX1 is
very sequence dependent. As shown in Fig. 4B, TREX1 effectively degrades an A17 substrate, but exhibits very limited activity with either C17 or U17 substrates, removing, at most, only a
few residues. Again, the D200N mutant is completely incapable
of degrading A17 (Fig. 4B, right panel). These findings indicate
that the similarity between TREX1 and E. coli RNase T extends
to its base specificity (23).
TREX1 Has Lower Affinity for ssRNA Than for ssDNA—Inasmuch as TREX1 is active on both ssDNA and ssRNA, we
directly compared these two activities. As shown in Fig. 5A,
TREX1 degrades both ssDNA and ssRNA in a distributive man-
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rRNAs (14, 17). To determine whether TREX1 also acts on
natural RNA substrates, we incubated purified TREX1 with a
native tRNA sample that had been 3⬘ end labeled with [3H]A, an
assay commonly used for RNase T (21). As shown in Fig. 5C,
TREX1 efficiently removes the [3H]AMP residue from tRNA,
amounting to 75% of the tRNA ends in 30 min. Essentially no
AMP is removed in the absence of added enzyme. This indicates that human TREX1 is active on native tRNA, again showing that its catalytic properties are similar to those of E. coli
RNase T (17).

Discussion
In this report, we demonstrate that the DNA exonuclease
TREX1, like all other members of the DEDD superfamily of
nucleases, is also an exoribonuclease. We suggest that TREX1 is
a human homolog of E. coli RNase T based on the following
observations: 1) TREX1 and RNase T share sequence similarity
(Fig. 7) (1, 2); 2) both TREX1 and RNase T need to form a
homodimer to exhibit nuclease activity (1, 15, 16, 24); 3) TREX1
and RNase T both display exoribonuclease and DNA exonuclease activity (this study and Ref. 17 for RNase T); 4) both
TREX1 and RNase T display a higher Km for ssRNA than for
ssDNA (this study and Refs. 17 and 18 for RNase T); and 5) both
TREX1 and RNase T discriminate against pyrimidine nucleotides for their exoribonuclease activities (this study and Ref. 23
for RNase T). Thus, TREX1 might be involved in RNA metabolism in human cells just as RNase T is in E. coli (14, 17). Indeed,
our data show that human TREX1, like RNase T, is competent

in trimming tRNA ends (Fig. 5C). It would be of considerable
interest to further examine TREX1 for possible roles in RNA
metabolism.
Analysis of the available TREX1 crystal structures reveals
that the substrate binding sites are open enough to accommodate the 2⬘ hydroxyls in an RNA substrate (9) (Fig. 6). The
closest approach between the enzyme and the 2⬘ positions on
the nucleic acid substrate is at the 3⬘ end in a co-crystal
structure of mouse TREX1 and a DNA substrate (9). The
residue closest to the 2⬘ position at the 3⬘ end of the substrate
has a short side chain (Ala-81 in mouse TREX1) and can
easily accommodate a hydroxyl group. This position (residue
81) in human TREX1 is also an alanine, and sequence alignment of TREX1 homologs suggests that this may be conserved, presumably to maintain sufficient space for binding
RNA substrates (Fig. 7).
Human TREX1 has three transcript variants with different
lengths of extra residues at the N terminus. The highest
expressed TREX1 variant in human cells is isoform b that
was used in this study (2). Earlier work failed to detect the
RNase activity of TREX1 (1). One likely possibility to explain
this result is that the TREX1 protein expressed in the earlier
work was the shortest isoform (isoform c), lacking 10 amino
acids at its N terminus compared with isoform b (1, 2, 18).
Such a change in TREX1 structure could affect its substrate
affinity or catalytic activity considering that the active site
residues (Asp-8 and Glu-10 in isoform c or Asp-18 and

FIGURE 7. Multiple sequence alignment of selected TREX1 and RNase T homologs. Human TREX1 (UniProt accession number Q9NSU2, isoform b) was
aligned with several putative TREX1 homologs as well as two RNase T sequences. Structure guided multiple sequence alignment was carried out using T-Coffee
and Expresso (32), with minor adjustments based on RNase T structures (33). Homologs were chosen to include sequence diversity, and are H2RDA8 from Pan
troglodytes, Q9BG99 from Bos taurus, Q5BK16 from Rattus norvegicus, Q91XB0 from Mus musculus, F6U4Q1 from Monodelphis domestica, G1KIA5 from Anolis
carolinensis, and the more distant (26% identity) from Danio rerio (zebrafish). RNase T sequences are from Pseudomonas aeruginosa (Q9HY82) and E. coli
(P30014). Sequence similarity is highlighted using ESPRIPT (34), and the secondary structure schematics shown are based on the mouse TREX1 structure (top;
Protein Data Bank code 3U6F, Ref. 9) and the E. coli RNase T structure (bottom; Protein Data Bank code 2IS3, Ref. 33). Residue 81 in human TREX1, closest to the
2⬘ position on the 3⬘ nucleotide at the cleavage site, is conserved as an alanine in TREX1 homologs (position marked with a green arrow).
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FIGURE 8. The N-terminal 1–10 truncation present in isoform c of TREX1 diminishes RNase activity. The protein concentrations of WT (isoform b, NCBI Ref.
sequence NP_338599.1) and isoform c (NCBI Ref. sequence NP_009179.2) of TREX1 were adjusted so that their activities against ssDNA (2 nM) were identical.
Under these same conditions their respective activities against ssRNA (2 nM) were determined. Assays were carried out at 37 °C for 20 min. Arrows point to
positions of the substrate and a 1-nt standard. % Sub indicates the percentage of remaining substrate.
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Glu-20 in isoform b) of TREX1 are located in the N-terminal
region (9, 25). To test this possibility, we purified isoform c
and compared its DNase and RNase activities with isoform b
(referred as WT in this study). Under conditions in which
both isoform b (WT) and isoform c show similar DNase
activity, isoform c fails to degrade the ssRNA substrate, in
contrast to isoform b (Fig. 8). These data explain the previous observation (1) and suggest that the structural difference
between isoform b and isoform c affects primarily the RNase
activity. In this regard, it will be interesting to examine the
DNase and RNase activities of the longest TREX1 isoform a
(2). Nevertheless, based on our data, it is clear that TREX1
isoform b possesses RNase activity, and that TREX1 is
closely related to E. coli RNase T, another nuclease that possesses both DNase and RNase activity (17).
Mutations in TREX1 are known to cause AGS1 (7, 26).
Moreover, the heterotrimeric endoribonuclease, RNase H2,
interacts with TREX1. Defects in the RNase H2 subunits,
namely RNASEH2B, RNASEH2C, and RNASEH2A, are
known to cause AGS2, AGS3, and AGS4 types of the disease,
respectively (26 –29). Although it is tempting to speculate
that the TREX1-RNase H2 complex functions as a holoRNase enzyme in removing RNA debris that may cause the
autoimmune response, it is possible that the endoribonuclease activity of RNase H2 first cuts RNA into smaller fragments and then the exoribonuclease activity of TREX1 further degrades the RNA fragments to nucleotides (Fig. 1, C
and D). It is therefore conceivable that defects in RNA degradation may contribute to accumulation of RNA species
and thus induce other aberrant autoimmune responses such
as systemic lupus erythematosus, chilblain lupus, and retinal
vasculopathy with cerebral leukodystrophy. It would be
interesting to investigate whether and how the exoribonuclease activity of TREX1 and the endoribonuclease activity of
RNase H2 coordinate with each other to achieve efficient
RNA removal.
The DNA exonuclease activity of TREX1 was shown to be
responsible for preventing HIV replication by degrading the
reverse-transcribed ssDNA and hiding the virus from detection by the immune system (12, 30). Beyond the proposed
DNA removal of the HIV virus in suppressing the immune
response (12, 30), it is also possible, based on our observations, that TREX1 may directly degrade the single-stranded
HIV RNA virus or the RNA/DNA hybrid (Fig. 2A) and contribute to suppression of HIV replication. Although it has
been shown that a knock-out of TREX1 causes aberrant
lysosomal biogenesis, which elicits innate immune responses and inhibits replication of RNA viruses (12, 13), it is
also likely that the RNase activity of TREX1 is directly
involved in degrading RNA virus and preventing it from
being duplicated.
In addition to the discovery of the exoribonuclease activity of
TREX1, we also describe an efficient protocol for enriching and
precleaning proteins that are associated with chromatin and
membranes. This protocol not only makes it possible to isolate
and purify high quality non-tagged human TREX1 protein for
this study, but it also provides a universal strategy for isolating
non-tagged membrane-bound and chromatin-bound proteins.
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